Home    Back

Genetic: ornithine transcarbamylase vector    (DrugBank: Ornithine)

1 disease
IDDisease name (Link within this page)Number of trials
251Urea cycle disorder1

251. Urea cycle disorder    [ 42 clinical trials,   45 drugs,   (DrugBank: 10 drugs),   4 drug target genes,   29 drug target pathways]
Searched query = "Urea cycle disorder", "N-acetylglutamate synthase deficiency", "NAGS deficiency", "Carbamoyl phosphate synthetase I deficiency", "CPS1 deficiency", "Ornithine transcarbamylase deficiency", "OTC deficiency", "Classic citrullinemia", "Citrullinemia type I", "Argininosuccinic aciduria", "Argininemia", "Hiperornitinemia-hiperamonemia-homocitrulinuria syndrome", "HHH syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 42 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00004307
(ClinicalTrials.gov)		December 199918/10/1999Study of Treatment and Metabolism in Patients With Urea Cycle DisordersTherapeutic and Metabolic Studies of Urea Cycle Disorders: Part A: Nitrogen Flux and Ureagenesis; Part B (Closed): Phase I Adenovirus Vector-Mediated Gene Therapy for Ornithine Transcarbamylase DeficiencyAmino Acid Metabolism, Inborn ErrorsBehavioral: Protein and calorie controlled diet;Genetic: Ornithine transcarbamylase vectorNational Center for Research Resources (NCRR)Baylor College of MedicineRecruiting6 Months64 YearsBoth66Phase 1United States